BN 80915, a lead compound of the homocamptothecin (hCPT) family, has entere
d clinical trials. BN 80915 is a difluoro-hCPT where the six-membered alpha
-hydroxylactone ring of camptothecin (CPT) is replaced by a seven-membered
beta -hydroxylactone ring. Preclinical data reported here show that in spi
te of the modification to the crucial E-ring of CPTs, BN 80915 retains topo
isomerase I poisoning activity as shown in living HT29 cells as well as in
cell-free assays, where BN 80915 always performs better than SN-38 or TPT,
In antiproliferative assays BN 80915 is also very potent as evidenced by IC
(50)s values consistently lower than those of SN38 in sensitive cell lines
as well as in their related multidrug-resistant lines overexpressing P-glyc
oprotein or multidrug resistance-associated protein. Furthermore, in human
plasma, in contrast to CPT analogs, the hydrolysis of BN 80915 is slow, lea
ding to improved plasma stability, and irreversible, thus avoiding toxicity
related to the accumulation of active principle during excretion in the ur
inary tract. These findings may account for the good in vivo efficacy obser
ved in PC3 xenograft experiments where BN 80915 administered orally at very
low doses doubled the tumor growth delay In comparison to CPT-11 administe
red i,p, Altogether, these results strongly support further development of
BN 80915, [(C) 2001 Lippincott Williams & Wilkins.].